Stelara Biosimilars: Save on Costs | Serve You Rx
- Serve You Rx, a pharmacy benefit manager based in Milwaukee, Wis., announced Thursday it has included two new biosimilars, Otulfi and Yesintek, on its formulary.
- Justin Jasniewski, CEO of Serve You Rx, said Stelara costs about $20,000 monthly.
- Serve You rx is taking a different approach by excluding high-cost reference products.The company created a "Biosimilar Advantage Formulary" that requires patients to use the lower-cost biosimilars first.
Serve You Rx is shaking up the pharmacy benefits landscape by slashing costs on Stelara treatments. By adding biosimilars Otulfi and Yesintek to its formulary, patients with Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis can save up to an astounding 96%. This bold move mandates the use of these lower-cost alternatives, offering a direct answer to high prescription prices. This approach is unique,as these options are prioritized to maximize savings for clients. Serve You Rx has partnered with Mark Cuban Cost Plus Drug Company and Waltz Health to ensure access and competitive pricing. This partnership between Serve You Rx and Waltz Health includes a digital platform directing prescriptions to the most suitable pharmacy driven by patient experience and price. See this news and more at News Directory 3. Discover what’s next in the world of biosimilars and potential expansions into cancer care and GLP-1s.
Serve You Rx Adds biosimilars to Formulary, Promising Cost Savings
Updated June 7, 2025
Serve You Rx, a pharmacy benefit manager based in Milwaukee, Wis., announced Thursday it has included two new biosimilars, Otulfi and Yesintek, on its formulary. These biosimilars are alternatives to Stelara, used in treating conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Justin Jasniewski, CEO of Serve You Rx, said Stelara costs about $20,000 monthly. The new biosimilars will allow clients to save approximately 96% with Otulfi and 90% with Yesintek. A biosimilar is clinically similar to a brand-name biologic drug but available at a lower cost.
Serve You rx is taking a different approach by excluding high-cost reference products.The company created a “Biosimilar Advantage Formulary” that requires patients to use the lower-cost biosimilars first.
Otulfi will be dispensed exclusively through Mark Cuban Cost Plus Drug Company (Cost Plus Drugs). Yesintek will be available through Serve You Rx’s specialty pharmacy network, powered by Waltz Health.Waltz Health’s platform, Waltz Connect, allows specialty pharmacies to compete based on quality, clinical outcomes, and price.
In April, Serve you Rx and Waltz Health announced a partnership to give Serve You Rx clients access to Waltz Connect. the platform directs prescriptions to the most suitable pharmacy based on factors like price and member experience.
Mark Thierer, co-founder and CEO at Waltz Health, said the companies plan to expand to more biosimilars in the future.
“This biosimilar proclamation is actually just the beginning,” Thierer said.”You’re going to see Waltz powering this intelligent routing for many high cost specialty meds… there’s a mountain of money to be saved.”
what’s next
Serve You Rx and Waltz Health plan to expand their biosimilar offerings, potentially including medications for cancer care and GLP-1s, aiming to further reduce costs and improve patient access.